Integration of stromal targeting agents with immune checkpoint therapy
基质靶向剂与免疫检查点疗法的整合
基本信息
- 批准号:10661808
- 负责人:
- 金额:$ 33.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-06-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AMD3100AllogenicAntibodiesAntigen TargetingAntsBioinformaticsBiometryCD44 geneCXCR4 Signaling PathwayCXCR4 geneCellsClinical TrialsCollaborationsCombination immunotherapyCytometryDataDesmoplasticEpigenetic ProcessEpitheliumFibroblastsFlow CytometryFocal Adhesion Kinase 1FutureGVAX Cancer VaccineGranulocyte-Macrophage Colony-Stimulating FactorGranzymeHumanHyaluronic AcidHyaluronic Acid BindingHyaluronidaseImmuneImmune System DiseasesImmune checkpoint inhibitorImmunohistochemistryImmunotherapyInfiltrationInterferon Type IIMalignant NeoplasmsMalignant neoplasm of pancreasMeasuresMediatingMemoryModelingMonitorMusMyelogenousMyeloid CellsMyeloid-derived suppressor cellsNeoadjuvant TherapyOperative Surgical ProceduresPD-1 inhibitorsPancreatic Ductal AdenocarcinomaPathway interactionsPatientsPhenotypePhosphorylation InhibitionPlayProductionPrognosisPublicationsRecombinantsRegulatory T-LymphocyteResectableRoleSignal PathwaySignal TransductionSortingStromal Cell-Derived Factor 1Suppressor-Effector T-LymphocytesT cell infiltrationT cell receptor repertoire sequencingT memory cellT-LymphocyteTechnologyTestingTumor BankTumor ImmunityTumor-associated macrophagesVaccinesanti-PD-1anti-PD1 antibodiesanti-tumor immune responseantigen-specific T cellscheckpoint therapycytotoxiceffector T cellexhaustionimmunoregulationimprovedinfiltrating duct carcinomainhibitorkinase inhibitormonocytemouse modelneoantigen vaccineneoantigensneoplastic cellnovelnovel strategiespancreatic cancer patientspancreatic ductal adenocarcinoma modelpancreatic stellate cellperipheral bloodprogrammed cell death protein 1receptorrecruitresponsesingle-cell RNA sequencingsmall molecule inhibitorstellate cellsynergismtargeted agenttraffickingtransmission processtumortumor microenvironmentultrasound
项目摘要
Pancreatic ductal adenocarcinoma (PDA) is enriched with activated stellate cells and hyaluronic acids (HA) that
contribute to the cancer’s poor prognosis. Our recent publication has shown that the PEGylated form of
recombinant hyaluronidase (PEGPH20), which degrades hyaluronic acid in the stroma, enhances the intra-
tumoral trafficking of effector T cells and anti-tumor efficacy of a PDA vaccine. We also demonstrated that the
effect of PEGPH20 is mediated by the CXCL12-CXCR4-CCR7 signaling axis that is transmitted from stromal
fibroblasts to myeloid cells and T cells. Focal adhesion kinase (FAK) also plays an integral role in modulating
pancreatic stellate cells and recruiting myeloid-derived suppressor cells (MDSCs), tumor-associated
macrophages (TAMs) and T regulatory cells (Tregs) into PDA mouse tumors. FAK inhibition can also enhance
antitumor activity when given in combination with immune checkpoint inhibitors (ICIs) that block PD-1. Therefore,
we hypothesize that targeting stromal/myeloid cell signals by FAK and HA-CXCR4 inhibition will enhance
antitumor immune responses by selectively recruiting high-quality effector memory T cells (Tem) into PDA
tumors. First, this project will examine PDA tumor microenvironment (TME) reprogramming following treatment
with stromal/myeloid cell targeting agents and ICIs in PDA mouse models. We will test combinations of
PEGPH20 or anti-CXCR4 antibody, with FAK inhibitor and anti-PD-1 antibody, for enhanced T cell infiltration
and function in murine PDAs. We will compare two different CXCL12/CXCR4 targeting agents: anti-mouse
CXCR4 antibody vs. small molecule inhibitor AMD3100, and evaluate whether lower HA/CXCR4 is associated
with improved response to PD-1 and FAK inhibitors in PDA tumors banked from a clinical trial testing anti-PD-1
and FAK inhibition as neoadjuvant therapy for surgically resectable PDA patients. Second, this project will dissect
mechanisms of cross-talk between FAK and HA-CXCR4 signaling pathways that regulate infiltration and function
of high-quality T cells in murine PDA. We will test the working hypotheses that PEGPH20 inhibits CD44 through
degrading HA; by inhibiting binding of HA to its receptor CD44, PEGPH20 inhibits the phosphorylation of FAK
reducing its inhibitory activity in Tem. Also, HA activates pFAK in CAFs to produce CXCL12, which in turn
activates CXCR4 on suppressive myeloid cells. Third, this project will explore combinations of FAK inhibition
and stroma/myeloid cell targeting agents, with ICIs for enhanced infiltration and function of high-quality
neoepitope-specific effector T cells in murine PDAs. Specifically, we will test the hypothesis that combining neo-
antigen T cell inducing approaches with FAK and HA/CXCR4 inhibitors and ICIs results in enhanced infiltration
and function of high quality, neoepitope-specific T cells in PDAs.
胰腺导管腺癌(PDA)富含活化的星状细胞和透明质酸(HA),
导致癌症预后不良的原因之一。我们最近的出版物表明,聚乙二醇化形式的
重组透明质酸酶(PEGPH20)可以降解基质中的透明质酸,增强基质内的
肿瘤转移效应T细胞和PDA疫苗的抗肿瘤效果。我们还演示了
PEGPH20的作用是由基质传递的CXCL12-CXCR4-CCR7信号轴介导的
成纤维细胞分化为髓系细胞和T细胞。粘着斑激酶(FAK)也在调节中起着不可或缺的作用
胰腺星状细胞和招募髓系来源的抑制细胞(MDSCs),肿瘤相关
巨噬细胞(TAMs)和T调节细胞(Tregs)进入PDA小鼠肿瘤。抑制FAK还可以增强
与阻断PD-1的免疫检查点抑制剂(ICIS)联合使用时具有抗肿瘤活性。因此,
我们假设,通过抑制FAK和HA-CXCR4靶向基质/髓系细胞信号将增强
PDA选择性募集高质量效应记忆T细胞(Tem)的抗肿瘤免疫应答
肿瘤。首先,这个项目将检查治疗后PDA肿瘤微环境(TME)的重新编程
在PDA小鼠模型中使用基质/髓系细胞靶向药物和ICIS。我们将测试以下几种组合
PEGPH20或抗CXCR4抗体与FAK抑制剂和抗PD-1抗体一起用于增强T细胞浸润
并在小鼠掌上电脑中发挥作用。我们将比较两种不同的CXCL12/CXCR4靶向制剂:抗鼠
CXCR4抗体与小分子抑制剂AMD3100的比较,并评估低HA/CXCR4是否相关
抗PD-1临床试验证实PDA肿瘤对PD-1和FAK抑制剂的反应有所改善
FAK抑制作为可手术切除的PDA患者的新辅助治疗。其次,本项目将剖析
调节渗透和功能的FAK和HA-CXCR4信号通路之间的串扰机制
在小鼠PDA中获得高质量的T细胞。我们将测试PEGPH20通过以下途径抑制CD44的工作假设
降解HA;PEGPH20通过抑制HA与其受体CD44的结合抑制FAK的磷酸化
降低其在Tem中的抑制活性。此外,HA激活CAF中的pFAK以产生CXCL12,进而
激活抑制髓系细胞上的CXCR4。第三,该项目将探索FAK抑制的组合
和间质/髓系细胞靶向剂,配合ICIS用于增强渗透和功能的高质量
小鼠PDA中新表位特异性效应T细胞。具体地说,我们将测试这一假设,即结合近地天体-
FAK、HA/CXCR4抑制剂和ICIS诱导抗原T细胞途径可增强浸润
以及PDA中高质量、新表位特异性T细胞的功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lei Zheng其他文献
Lei Zheng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lei Zheng', 18)}}的其他基金
Integration of stromal targeting agents with immune checkpoint therapy
基质靶向剂与免疫检查点疗法的整合
- 批准号:
10408084 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Structure and function of a metabolic pacemaker in bacterial cell membrane
细菌细胞膜代谢起搏器的结构和功能
- 批准号:
10280369 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Structure and function of a metabolic pacemaker in bacterial cell membrane
细菌细胞膜代谢起搏器的结构和功能
- 批准号:
10652472 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Structure and function of a metabolic pacemaker in bacterial cell membrane
细菌细胞膜代谢起搏器的结构和功能
- 批准号:
10457395 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Structure and function of a metabolic pacemaker in bacterial cell membrane
细菌细胞膜代谢起搏器的结构和功能
- 批准号:
10796719 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Annexin A2 as a mediator of pancreatic cancer metastases
膜联蛋白 A2 作为胰腺癌转移的介质
- 批准号:
8579467 - 财政年份:2013
- 资助金额:
$ 33.76万 - 项目类别:
Annexin A2 as a mediator of pancreatic cancer metastases
膜联蛋白 A2 作为胰腺癌转移的介质
- 批准号:
8712421 - 财政年份:2013
- 资助金额:
$ 33.76万 - 项目类别:
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancer
探究胰腺癌肿瘤微环境中肿瘤细胞与神经之间的相互作用
- 批准号:
9764752 - 财政年份:2013
- 资助金额:
$ 33.76万 - 项目类别:
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancer
探究胰腺癌肿瘤微环境中肿瘤细胞与神经之间的相互作用
- 批准号:
10578764 - 财政年份:2013
- 资助金额:
$ 33.76万 - 项目类别:
Interrogate the interaction between tumor cells and nerves in the tumor microenvironment of pancreatic cancer
探究胰腺癌肿瘤微环境中肿瘤细胞与神经之间的相互作用
- 批准号:
10358637 - 财政年份:2013
- 资助金额:
$ 33.76万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 33.76万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 33.76万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 33.76万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 33.76万 - 项目类别:
Grant-in-Aid for Scientific Research (B)